SOP for EC/IRB notifications at closeout – Clinical Research Made Simple https://www.clinicalstudies.in Trusted Resource for Clinical Trials, Protocols & Progress Sat, 27 Sep 2025 00:14:33 +0000 en-US hourly 1 https://wordpress.org/?v=6.9.1 SOP for Study Closeout (Site and Sponsor) https://www.clinicalstudies.in/sop-for-study-closeout-site-and-sponsor/ Sat, 27 Sep 2025 00:14:33 +0000 ]]> https://www.clinicalstudies.in/?p=7041 Read More “SOP for Study Closeout (Site and Sponsor)” »

]]>
SOP for Study Closeout (Site and Sponsor)

{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-study-closeout-site-and-sponsor”
},
“headline”: “SOP for Study Closeout (Site and Sponsor)”,
“description”: “This SOP defines the standardized process for study closeout activities at both site and sponsor levels, including TMF/ISF reconciliation, IP accountability, subject follow-up, regulatory notifications, and archiving, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}

Standard Operating Procedure for Study Closeout (Site and Sponsor)

SOP No. CR/OPS/101/2025
Supersedes NA
Page No. 1 of 48
Issue Date 26/08/2025
Effective Date 01/09/2025
Review Date 01/09/2026

Purpose

The purpose of this SOP is to outline the procedures for clinical study closeout at both the site and sponsor levels. It ensures all regulatory, ethical, and operational requirements are met prior to study termination, including proper IP reconciliation, TMF/ISF finalization, subject follow-up, regulatory notifications, and archiving of study materials.

Scope

This SOP applies to sponsors, CROs, investigators, site staff, QA, and vendors involved in clinical trial conduct. It covers all site-level and sponsor-level closeout activities for interventional and non-interventional studies across all therapeutic areas.

Responsibilities

  • Sponsor: Oversees study-wide closeout activities, ensures TMF completeness, and regulatory submissions.
  • Investigator: Completes ISF closeout, subject follow-up, and IP accountability.
  • CRA/Monitor: Performs site closeout visits and ensures compliance with closeout checklist.
  • QA: Audits TMF/ISF for completeness prior to closeout.
  • Archivist: Archives study documents in compliance with retention timelines.

Accountability

The Sponsor’s Clinical Operations Head is accountable for ensuring study closeout procedures are completed. Investigators are accountable for site-level closeout activities. QA is accountable for verifying regulatory compliance.

Procedure

1. Site Closeout Preparation
1.1 Confirm completion of subject visits and follow-up activities.
1.2 Reconcile IP and document returns/destruction in IP Reconciliation Log.
1.3 Ensure all data queries are resolved prior to database lock.

2. Site Closeout Visit
2.1 CRA conducts site closeout visit using Closeout Checklist (Annexure-1).
2.2 Review ISF for completeness, ensure informed consent forms, source data, and essential documents are in place.
2.3 Document findings in Site Closeout Visit Report.

3. Sponsor-Level Closeout
3.1 Reconcile TMF and verify completeness using TMF Index.
3.2 Ensure regulatory submissions (e.g., final CSR, registry updates) are initiated.
3.3 Notify EC/IRB and regulators of study closure.

4. Archiving
4.1 Archive ISF and TMF in compliance with ICH GCP and regional regulations.
4.2 Maintain Archive Log (Annexure-2).

5. Subject Communication
5.1 Provide subjects with final study updates as per protocol.
5.2 Ensure ongoing safety follow-up for unresolved AEs.

6. Documentation
6.1 Maintain Closeout Documentation Log (Annexure-3).
6.2 Ensure all final closeout reports are signed by responsible parties.

Abbreviations

  • SOP: Standard Operating Procedure
  • CRA: Clinical Research Associate
  • QA: Quality Assurance
  • IP: Investigational Product
  • TMF: Trial Master File
  • ISF: Investigator Site File
  • CSR: Clinical Study Report
  • AE: Adverse Event
  • EC/IRB: Ethics Committee/Institutional Review Board

Documents

  1. Site Closeout Checklist (Annexure-1)
  2. Archive Log (Annexure-2)
  3. Closeout Documentation Log (Annexure-3)

References

Version: 1.0

Approval Section

Prepared By Ravi Kumar, Clinical Research Associate
Checked By Sunita Reddy, QA Officer
Approved By Dr. Anil Sharma, Head Clinical Operations

Annexures

Annexure-1: Site Closeout Checklist

Activity Status Remarks
All subject visits completed Yes Final subject follow-up done
IP accountability completed Yes Returned/destroyed

Annexure-2: Archive Log

Date Document Type Location Archived By
15/09/2025 TMF Central Archive Archivist

Annexure-3: Closeout Documentation Log

Date Document Prepared By Reviewed By Status
20/09/2025 Site Closeout Report CRA QA Officer Completed

Revision History

Revision Date Revision No. Revision Details Reason for Revision Approved By
26/08/2025 00 Initial version New SOP creation Head Clinical Operations

For more SOPs visit: Pharma SOP

]]>